Business Wire

Xsolla and Long Tale Games Launch Charity Campaign With Life Is Feudal to Support Games for Change

Share

Xsolla, a global video game commerce company, has partnered with Long Tale Games to launch a charity campaign. 50% of the proceeds from the 3-month subscription package to Life is Feudal will be donatedto Games For Change. This initiative, running until December 31st, reflects Xsolla’s commitment to leveraging the power of gaming to drive positive change.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241031878088/en/

(Graphic: Xsolla)

The campaign offers players an exciting adventure in Life is Feudal: MMO and allows them to make a tangible impact. With half of each 3-month subscription supporting educational programs, civic engagement initiatives, and social impact projects, the campaign demonstrates how gaming can foster a better future through the power of play. Players are empowered to engage with a meaningful cause, proving that games are more than just entertainment—they are a way to support causes that matter.

"Gaming is not just about entertainment; it's about community and the ability to make a meaningful difference," said Chris Hewish, Chief Strategy Officer at Xsolla. "Supporting Games For Change aligns with our mission to address key issues in education, civic engagement, and social impact through gaming. This campaign fosters an inclusive gaming community while inspiring change through play."

"Games For Change is thrilled to be a part of this initiative, highlighting how gamers, developers, and creators come together to create positive social impact," said Susanna Pollack, President of Games For Change. "Through this partnership with Xsolla and Long Tale Games, we aim to empower more creators to develop engaging, educational, and inspiring experiences beyond entertainment. The funds raised will directly support our mission to harness the power of games and immersive media for social good, driving meaningful change in communities worldwide."

For more information, please see the Long Tale Games and Games For Change Campaign Here: https://x.la/gamesforchange-lif

These campaigns underscore Xsolla’s dedication to social responsibility and the gaming community's commitment to leveraging their platforms for the greater good.

About Xsolla

Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch, and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in Montreal, London, Berlin, Beijing, Guangzhou, Seoul, Tokyo, Kuala Lumpur, Raleigh, and cities around the world, Xsolla supports major gaming titles like Valve, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, and more.

For additional information and to learn more, please visit xsolla.com

Twitter (X):@Xsolla | Facebook:Xsolla | Instagram:@xsolla | LinkedIn:Xsolla

About Long Tale Games

Long Tale Games (LTG) is a multiverse publisher set on reinvigorating legendary games with fresh energy and employing innovative monetization and user acquisition techniques. With a diverse portfolio that includes everything from classic to web3 games, LTG leverages industry expertise to channel, port, further develop, and support the marketing of hidden gems and classics, ensuring each project gets a tailored approach. At its core, LTG is powered by dedicated industry veterans who believe in a community-driven strategy, involving players in the development process to breathe new life into every game, proving their dedication to reviving beloved titles and fostering the growth of new ventures in the gaming world.

For more information, please visit longtalegames.com

Twitter (X):@LifeisFeudal | Facebook:Life is Feudal

About Games For Change

Since 2004, Games For Change (G4C) has empowered game creators and innovators to drive real-world change — using games and immersive media to help people learn, improve their communities, and make the world a better place. G4C partners with technology and gaming companies, nonprofits, foundations, and government agencies to run world-class events, public arcades, design challenges, and youth programs. G4C supports a global community of game developers working on using games to tackle real-world challenges, from humanitarian conflicts to climate change and education.

LinkedIn:Games For Change | Twitter (X):@G4C | Facebook:Games For Change

View source version on businesswire.com: https://www.businesswire.com/news/home/20241031878088/en/

Contacts

Media Contact
Derrick Stembridge
Global Director of Public Relations, Xsolla
d.stembridge@xsolla.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in

Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration

Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release

Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release

Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of

Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye